HTC Launching First Ever Honeycomb Tablet Next Week?
We recently showed you a shot of HTC’s first ever Honeycomb tablet, codenamed Puccini. It will be rocking Honeycomb along with HTC’s Sense UI. We’re expecting a dual-core processor and HTC’s Scribe pen as well. HTC is holding an event in London on June 27, and word on the street is that they’ll officially announced the tablet there. In the past, HTC has announced products like the Hero, Desire Z, and Desire HD in London, so we can expect something big from them next week.
We haven’t heard about any carrier launches, but it will likely launch as an international WiFi device, and then find its way to the States, much like the Flyer. We’ll try to do some more digging before next Monday, but we want to hear from you, our loyal readers. Are you as excited as we are about an HTC Honeycomb tablet? Sound off in the comments, or on our Facebook Wall!
You might also like
Samsung has started sending out invitations for the upcoming Galaxy Note 3 announcement. Set to kick off on September 4, the emails are tagged as “Note the date” instead of
MetroPCS and Rhapsody have paired together to offer a new service for subscribers to the no-contract wireless provider.Effective today, anyone who has an Android phone with a $60 monthly rate
Without knowing all the details, it stuns me that record labels in America continue to be very short sighted about the fact that the vast majority of consumers get their music digitally from the internet. Perhaps they are still smarting over the Napster debacle from the 90’s, but if an internet giant like Google came to me and said, “Hey, let’s launch a killer service that all of our users will have access to and will get you guys paid, but it will be in a different way than you are used to.”, I would sit up and listen and most likely act. Not so with the current major recording companies, as Engadget is reporting that someone has leaked that Google Music will be announced today at I/O, but as a cloud storage and streaming service rather than a subscription based offering. And the labels wonder why the continue to hemorrhage money.